<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615974</url>
  </required_header>
  <id_info>
    <org_study_id>LM101-01-103</org_study_id>
    <nct_id>NCT05615974</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors</brief_title>
  <official_title>A Phase I/II, Open-label, Dose Escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of LM-101 Injection as a Single Agent or Combination Therapy in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LaNova Medicines Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LaNova Medicines Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD)&#xD;
      and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in&#xD;
      patients with advanced malignant tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2023</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limitingtoxicity (DLT)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse event (SAE)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature in ℃</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse in BPM(Beat per Minute)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure in mmHg</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight in Kg</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height in centimeter</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests-Blood Routine examination</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests-Urine Routine test</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests-Blood biochemistry</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests- Coangulation function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG(Eastern Cooperative Oncology Group) score</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter:Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Area Under the Concentration-time Curve(AUC)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Steady State Maximum Concentration(Cmax,ss)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Steady State Minimum Concentration(Cmin,ss)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Systemic Clearance at Steady State (CLss)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Accumulation Ratio (Rac)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Elimination Half-life (t1/2)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Volume of Distribution at Steady-State (Vss)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Degree of Fluctuation (DF)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of LM-101</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2; Anti-Drug antibody and Nab (if neccessary) will be tested.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor Occupancy of LM-101</measure>
    <time_frame>48 weeks</time_frame>
    <description>Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker correlation (CD8/CD47/CD68/CD163/PD-L1)</measure>
    <time_frame>112 weeks</time_frame>
    <description>Phase 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Month</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) in percentage</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS) in Month</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in Month</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of target lesions from baseline in Millimeter.</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: AE/SAE (Number of participants with treatment-related adverse events as assessed by CTCAE v5.0)</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature in ℃</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse in BPM(Beat per Minute)</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure in mmHg</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in Kg</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height in centimeter</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests-Blood Routine examination</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests-Urine Routine test</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests-Blood biochemistry</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests- Coangulation function</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram (ECG) in RR, PR, QRS, QT, QTcF etc.</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG(Eastern Cooperative Oncology Group) score</measure>
    <time_frame>64 weeks</time_frame>
    <description>Phase 2</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>LM101 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LM101 combination therapy exploratory</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LM101 combination expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LM101</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LM101 Dose Escalation</arm_group_label>
    <arm_group_label>LM101 combination expansion</arm_group_label>
    <arm_group_label>LM101 combination therapy exploratory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LM101 combination expansion</arm_group_label>
    <arm_group_label>LM101 combination therapy exploratory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LM101 combination expansion</arm_group_label>
    <arm_group_label>LM101 combination therapy exploratory</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envafolimab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>LM101 combination expansion</arm_group_label>
    <arm_group_label>LM101 combination therapy exploratory</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are willing to participate in the study and sign the informed consent&#xD;
             form (ICF) prior to any procedure.&#xD;
&#xD;
          2. Aged ≥18 years old, male or female.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.&#xD;
&#xD;
          4. Life expectancy ≥ 3 months.&#xD;
&#xD;
          5. Subjects must have histological or cytological confirmation of recurrent or refractory&#xD;
             advanced solid tumors, and have progressed on standard therapy.&#xD;
&#xD;
          6. At least one evaluable lesion.&#xD;
&#xD;
          7. Subjects must show appropriate organ and marrow function in laboratory examinations&#xD;
             within 7 days prior to the first dose:&#xD;
&#xD;
          8. Women of childbearing potential (WOCBP) must agree to use highly effective methods of&#xD;
             contraception prior to study entry, during the study and for 6 months after the last&#xD;
             dose of study drug.&#xD;
&#xD;
          9. Subjects who can communicate well with investigators and understand and adhere to the&#xD;
             requirements of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has received prior investigational therapy directed at CD47 or SIRPα.&#xD;
&#xD;
          2. Subjects has participated in any other interventional clinical trial within 21 days&#xD;
             prior to the first dosing of LM-101.&#xD;
&#xD;
          3. Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101,&#xD;
             including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.&#xD;
&#xD;
          4. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of&#xD;
             CTCAE v5.0.&#xD;
&#xD;
          5. Subjects with symptomatic/active central nervous system (CNS) metastases.&#xD;
&#xD;
          6. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites&#xD;
             requiring recurrent drainage procedures.&#xD;
&#xD;
          7. Subjects with known hypersensitivity to antibody therapy.&#xD;
&#xD;
          8. Subjects who take systemic corticosteroids (&gt; 10 mg daily prednisone equivalents) or&#xD;
             other systemic immunosuppressive medicationswithin 2 weeks prior to the first dosing&#xD;
             of LM-101.&#xD;
&#xD;
          9. Subjects with the known history of autoimmune disease with the exception of subjects&#xD;
             with a history of autoimmune-related hypothyroidism on a stable dose of&#xD;
             thyroid-replacement hormone.&#xD;
&#xD;
         10. Subject who has interstitial lung disease or a history of pneumonitis that required&#xD;
             oral or intravenous glucocorticoids to assist with management.&#xD;
&#xD;
         11. Use of any live attenuated vaccines within 28 days prior to the first dosing of&#xD;
             LM-101.&#xD;
&#xD;
         12. Subjects who received major surgery or interventional treatment within 28 days prior&#xD;
             to the first dosing of LM-101 (excluding tumor biopsy, puncture, etc.).&#xD;
&#xD;
         13. Subjects who have uncontrolled or severe illness.&#xD;
&#xD;
         14. Subjects who have a history of immunodeficiency disease.&#xD;
&#xD;
         15. HIV infection, active tuberculosis or active HBV and HCV infection.&#xD;
&#xD;
         16. Subjects who have other active invasive cancers, other than the one treated in this&#xD;
             trial, within 5 years prior to screening.&#xD;
&#xD;
         17. Child-bearing potential female who have positive results in pregnancy test or are&#xD;
             lactating.&#xD;
&#xD;
         18. Subject who is judged as not eligible to participate in this study by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alex Yuan</last_name>
    <phone>+8615901815211</phone>
    <email>alexyuan@lanovamed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingqing Cai</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>October 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>March 7, 2023</last_update_submitted>
  <last_update_submitted_qc>March 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

